We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Even now, with the dip in value, its price-to-earnings (P/E) multiple is close to 80, which still isn't terribly cheap ... Eli Lilly still has a couple of fantastic drugs in Mounjaro and Zepbound ...

Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s. However, sales of Mounjaro/Zepbound were ... the Zacks Retail - Discount Stores industry over ...

Zepbound has ... the stock is very cheap. Given its valuation and the growth still in front of it with GLP-1 drugs, investors can look to buy the dip in Eli Lilly stock. JPMorgan Chase is an ...

Late last year, regulators approved Zepbound as a treatment ... can get the stock at any kind of a discount, you shouldn't hesitate to take it. I think Eli Lilly's valuation can rise a whole ...

GLP-1 drugs still lead the way for Eli Lilly Turning to its GLP-1 drugs, Lilly is looking for sales of Mounjaro to be $3.5 billion and $1.9 billion for Zepbound ... the stock is very cheap.